Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) announced it will exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC), scheduled for May 12-16, 2026, in Padua, Italy. The meeting, hosted by the University of Padova, brings together over 1,000 specialists from 32 European countries and beyond, making it the largest global association in congenital cardiology.
The scientific program centers on advanced cardiovascular imaging and artificial intelligence, areas where Ventripoint is making significant clinical progress. The company will exhibit alongside its European distributor, AngioPro, focusing on how its VMS+™ platform supports the evolution of cardiac function monitoring over time in congenital heart disease (CHD) patients. This approach aligns with the 2020 ESC Guidelines for Adult Congenital Heart Disease, co-endorsed by AEPC, which identify CHD as a lifelong chronic condition requiring structured follow-up and echocardiography as the key modality for longitudinal ventricular function assessment (Baumgartner et al., European Heart Journal, 2021).
Ventripoint’s priority for 2026 is accelerating the integration of VMS+™ into routine clinical practice. The latest release, VMS+™ 4.0, was designed to streamline workflows, reduce assessment time, and make advanced cardiac analysis accessible at the point of care. At the first echocardiogram, VMS+™ provides accurate volumetric measurements equivalent to MRI, offering early insights that support clinical decision-making and effective patient management across a lifetime of care.
“AEPC represents the heart of the European congenital cardiology community, and we are proud to be part of it,” said Hugh MacNaught, President and CEO of Ventripoint. “VMS+™ delivers fast, affordable, and accessible volumetric cardiac assessments with accuracy comparable to MRI – giving clinicians the confidence they need to manage their patients at every stage of life.”
Ventripoint is an industry leader in applying artificial intelligence to echocardiography. Its VMS+™ product family, powered by proprietary KBR technology, delivers MRI-equivalent volumetric cardiac measurements. The system is compatible with ultrasound systems from all major vendors and holds regulatory approvals in the U.S., Europe, and Canada.
